India’s drug regulator has begun drafting new guidelines for high-risk solvents used in children’s medicines, after deaths tied to contaminated cough syrups. Investigators reportedly found the solvents can carry toxic impurities. The regulator is consulting pharmaceutical companies to review current solvent practices and push safer alternatives, a move aimed at preventing further tragedies involving Indian-made syrups.
With at least 20 MP children blamed for deaths linked to Coldrif, investigators are zeroing in on how diethylene glycol, a highly toxic substance, could have ended up in cough syrup made by Tamil Nadu-based Sresan Pharma. ET Prime reports the central question is the supply chain and manufacturing controls that allowed a lethal contaminant to reach patients.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
